Cargando…

Willingness to use and preferences for long‐acting injectable PrEP among sexual and gender minority populations in the southern United States, 2021–2022: cross‐sectional study

INTRODUCTION: Long‐acting injectable (LAI) pre‐exposure prophylaxis (PrEP) for HIV prevention was approved by the U.S. Food and Drug Administration in 2021. LAI PrEP is more effective than oral PrEP. However, it is not clear whether the groups most at risk of HIV in the United States will use LAI Pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Schoenberg, Paige, Edwards, O. Winslow, Merrill, Leland, Martinez, Cristian Acero, Stephenson, Rob, Sullivan, Patrick S., Jones, Jeb
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10034617/
https://www.ncbi.nlm.nih.gov/pubmed/36951057
http://dx.doi.org/10.1002/jia2.26077
_version_ 1784911253882273792
author Schoenberg, Paige
Edwards, O. Winslow
Merrill, Leland
Martinez, Cristian Acero
Stephenson, Rob
Sullivan, Patrick S.
Jones, Jeb
author_facet Schoenberg, Paige
Edwards, O. Winslow
Merrill, Leland
Martinez, Cristian Acero
Stephenson, Rob
Sullivan, Patrick S.
Jones, Jeb
author_sort Schoenberg, Paige
collection PubMed
description INTRODUCTION: Long‐acting injectable (LAI) pre‐exposure prophylaxis (PrEP) for HIV prevention was approved by the U.S. Food and Drug Administration in 2021. LAI PrEP is more effective than oral PrEP. However, it is not clear whether the groups most at risk of HIV in the United States will use LAI PrEP. Willingness to use LAI PrEP and preference for LAI versus oral PrEP has not been reported for sexual and gender minority (SGM) people in the southern United States, where the HIV epidemic is concentrated. Our goal was to assess willingness to use LAI PrEP and preference for oral versus LAI PrEP among SGM people in the southern United States and to assess differences in willingness by demographics and sexual behaviour. METHODS: We conducted an online, cross‐sectional survey of SGM people aged 15–34 years in the southern United States (n = 583). Participants reported willingness to use LAI PrEP and preferences for LAI PrEP versus daily oral PrEP. We assessed bivariate associations and adjusted prevalence ratios for the LAI‐PrEP‐related outcomes and key demographic and behavioural characteristics. RESULTS: Overall, 68% of all participants (n = 393) reported being willing to use LAI PrEP that provides protection against HIV for 3 months. Of those, most (n = 320, 81%) indicated a preference for using LAI PrEP, compared to a daily oral pill or no preference. Willingness to use LAI PrEP was more common among transgender and non‐binary participants and participants who engaged in condomless anal intercourse in the last 6 months. Hispanic participants were more likely and non‐Hispanic Black participants were less likely to report willingness to use LAI PrEP compared to non‐Hispanic White participants. CONCLUSIONS: Willingness to use LAI PrEP was high among SGM people in the southern United States, although there were some important differences in willingness based on demographic characteristics. Decreased willingness to use LAI PrEP among groups who are disproportionately affected by the HIV epidemic, such as non‐Hispanic Black SGM people, could exacerbate existing disparities in HIV incidence. LAI PrEP is an acceptable option among SGM populations in the southern United States, but strategies will be needed to ensure equitable implementation.
format Online
Article
Text
id pubmed-10034617
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-100346172023-03-24 Willingness to use and preferences for long‐acting injectable PrEP among sexual and gender minority populations in the southern United States, 2021–2022: cross‐sectional study Schoenberg, Paige Edwards, O. Winslow Merrill, Leland Martinez, Cristian Acero Stephenson, Rob Sullivan, Patrick S. Jones, Jeb J Int AIDS Soc Short Report INTRODUCTION: Long‐acting injectable (LAI) pre‐exposure prophylaxis (PrEP) for HIV prevention was approved by the U.S. Food and Drug Administration in 2021. LAI PrEP is more effective than oral PrEP. However, it is not clear whether the groups most at risk of HIV in the United States will use LAI PrEP. Willingness to use LAI PrEP and preference for LAI versus oral PrEP has not been reported for sexual and gender minority (SGM) people in the southern United States, where the HIV epidemic is concentrated. Our goal was to assess willingness to use LAI PrEP and preference for oral versus LAI PrEP among SGM people in the southern United States and to assess differences in willingness by demographics and sexual behaviour. METHODS: We conducted an online, cross‐sectional survey of SGM people aged 15–34 years in the southern United States (n = 583). Participants reported willingness to use LAI PrEP and preferences for LAI PrEP versus daily oral PrEP. We assessed bivariate associations and adjusted prevalence ratios for the LAI‐PrEP‐related outcomes and key demographic and behavioural characteristics. RESULTS: Overall, 68% of all participants (n = 393) reported being willing to use LAI PrEP that provides protection against HIV for 3 months. Of those, most (n = 320, 81%) indicated a preference for using LAI PrEP, compared to a daily oral pill or no preference. Willingness to use LAI PrEP was more common among transgender and non‐binary participants and participants who engaged in condomless anal intercourse in the last 6 months. Hispanic participants were more likely and non‐Hispanic Black participants were less likely to report willingness to use LAI PrEP compared to non‐Hispanic White participants. CONCLUSIONS: Willingness to use LAI PrEP was high among SGM people in the southern United States, although there were some important differences in willingness based on demographic characteristics. Decreased willingness to use LAI PrEP among groups who are disproportionately affected by the HIV epidemic, such as non‐Hispanic Black SGM people, could exacerbate existing disparities in HIV incidence. LAI PrEP is an acceptable option among SGM populations in the southern United States, but strategies will be needed to ensure equitable implementation. John Wiley and Sons Inc. 2023-03-23 /pmc/articles/PMC10034617/ /pubmed/36951057 http://dx.doi.org/10.1002/jia2.26077 Text en © 2023 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Short Report
Schoenberg, Paige
Edwards, O. Winslow
Merrill, Leland
Martinez, Cristian Acero
Stephenson, Rob
Sullivan, Patrick S.
Jones, Jeb
Willingness to use and preferences for long‐acting injectable PrEP among sexual and gender minority populations in the southern United States, 2021–2022: cross‐sectional study
title Willingness to use and preferences for long‐acting injectable PrEP among sexual and gender minority populations in the southern United States, 2021–2022: cross‐sectional study
title_full Willingness to use and preferences for long‐acting injectable PrEP among sexual and gender minority populations in the southern United States, 2021–2022: cross‐sectional study
title_fullStr Willingness to use and preferences for long‐acting injectable PrEP among sexual and gender minority populations in the southern United States, 2021–2022: cross‐sectional study
title_full_unstemmed Willingness to use and preferences for long‐acting injectable PrEP among sexual and gender minority populations in the southern United States, 2021–2022: cross‐sectional study
title_short Willingness to use and preferences for long‐acting injectable PrEP among sexual and gender minority populations in the southern United States, 2021–2022: cross‐sectional study
title_sort willingness to use and preferences for long‐acting injectable prep among sexual and gender minority populations in the southern united states, 2021–2022: cross‐sectional study
topic Short Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10034617/
https://www.ncbi.nlm.nih.gov/pubmed/36951057
http://dx.doi.org/10.1002/jia2.26077
work_keys_str_mv AT schoenbergpaige willingnesstouseandpreferencesforlongactinginjectableprepamongsexualandgenderminoritypopulationsinthesouthernunitedstates20212022crosssectionalstudy
AT edwardsowinslow willingnesstouseandpreferencesforlongactinginjectableprepamongsexualandgenderminoritypopulationsinthesouthernunitedstates20212022crosssectionalstudy
AT merrillleland willingnesstouseandpreferencesforlongactinginjectableprepamongsexualandgenderminoritypopulationsinthesouthernunitedstates20212022crosssectionalstudy
AT martinezcristianacero willingnesstouseandpreferencesforlongactinginjectableprepamongsexualandgenderminoritypopulationsinthesouthernunitedstates20212022crosssectionalstudy
AT stephensonrob willingnesstouseandpreferencesforlongactinginjectableprepamongsexualandgenderminoritypopulationsinthesouthernunitedstates20212022crosssectionalstudy
AT sullivanpatricks willingnesstouseandpreferencesforlongactinginjectableprepamongsexualandgenderminoritypopulationsinthesouthernunitedstates20212022crosssectionalstudy
AT jonesjeb willingnesstouseandpreferencesforlongactinginjectableprepamongsexualandgenderminoritypopulationsinthesouthernunitedstates20212022crosssectionalstudy